Skip to content
Homepage
Author:
TransCode Therapeutics, Inc.
Posted Date:
June 8, 2026
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
TransCode Therapeutics, Inc.
June 8, 2026
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
TransCode Therapeutics, Inc.
June 3, 2026
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
TransCode Therapeutics, Inc.
May 27, 2026
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics, Inc.
May 3, 2026
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company’s Runway into Late 2027/Early 2028
TransCode Therapeutics, Inc.
April 30, 2026
1
2
Next
